What costs $1,349 in the US is only $92 in the UK. Why are weight loss drugs so pricey?
About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce risks with obesity.
TennCare requesting $118M for popular weight loss, Type 2 diabetes drugs
TennCare is federally required to cover GLP-1 drugs; of the $118M in the cost increase request, more than $76 million would be coming from federal dollars.
Weight loss, diabetes drugs can also protect kidneys: Study
The popular glucagon-like peptide-1 (GLP-1) receptor agonists known to help in weight loss as well as manage blood sugar can also protect the kidneys, regardless of diabetes status, finds a study
Weight-loss drugs can improve kidney health, study finds
Weight-loss drugs can reduce the risk of worsening kidney function, kidney failure and dying from kidney disease by a fifth, according to a study. Glucagon-like peptide-1 (GLP-1) receptor agonists are a family of medications that help people shed the pounds,
Diabetes drug shows promise in protecting kidneys
Researchers evaluated the effects of SGLT2 inhibitors in protecting the kidneys, showing that the drugs might help improve oxygenation in these organs.
Popular diabetes and obesity drugs also protect kidneys, study suggests
Popular diabetes and obesity drugs also protect kidneys, study suggests - The combined reduction in the risk of kidney failure, worsening kidney function and death due to kidney disease was 19%, researchers found.
McKnight's Long-Term Care News20h
White House eyes plan to cover anti-obesity drugs for people on Medicare, Medicaid
The Biden administration has proposed a new plan to expand coverage of glucagon-like peptide-1 (GLP-1) medications such ...
Biden wants Medicare, Medicaid to cover pricey weight loss drugs such as Wegovy
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
As many as 1 in 5 people won't lose weight with GLP-1 drugs, experts say
About 20% of patients — as many as 1 in 5 — may not respond well to medications like Mounjaro and Wegovy, according to ...
Medscape6h
Diabetes Drugs Promising for Alcohol Use Disorder
Compared with standard AUD medications, the use of semaglutide and liraglutide was linked to a lower risk for alcohol use ...
Popular diabetes and obesity drugs also protect kidneys, study shows
The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...
Health and Me on MSN4h
When Ozempic And Wegovy Fail To Work- Why GLP-1 Drugs Aren’t The Magic Bullet For Everyone
When Ozempic and Wegovy don’t work, genetic differences, medical conditions, or side effects could be to blame. Is it normal, ...
News Medical on MSN6d
Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption
The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...
CMAJ1d
Glucagon-like peptide-1 receptor agonists for treating chronic kidney disease in patients with type 2 diabetes
In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2, subcutaneous semaglutide reduced the ...
Newsday5h
Wegovy, Mounjaro: Suffolk County among employers rethinking access to costly weight loss drugs
Those on the medications, known as GLP-1s or glucagon-like peptide-1, will additionally weigh in four times a month on ...
News Medical1d
GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes
The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and ...